Search
Close this search box.
Search
Subscriber Log In

Competitive Intelligence Insights: Cell & Gene Therapy

cell-gene-abstract-image

The number of cell and gene therapy (C&GT)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is […]

In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar

Case-You-Missed-Three-Things-We-Learned-Our-Gene-Editing-Webinar-featured-image

Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]

Five Questions About the Future of Gene Editing

Five-Questions-About-Future-Gene-Editing-featured-image

Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]

Genetic Medicine: The Next Gene-eration

Genetic-Medicine-Next-Gene-eration-featured-image

Once upon a time, a gene therapy player could release data on a handful of subjects and see its share price rocket. The sector was riding high after the landmark approvals of Luxturna and Zolgensma, and big pharma was keen to buy into this space. Valuations surged as investors clamoured for a piece of the […]